157 related articles for article (PubMed ID: 38379420)
1. Mechanism of action of adapalene for treating EGFR-TKI-induced skin disorder.
Mimura C; Nagano T; Miwa N; Matsumura K; Yamada J; Satoh H; Suraya R; Hazama D; Tamura D; Yamamoto M; Tachihara M; Nishimura Y; Kobayashi K
Thorac Cancer; 2024 Mar; 15(9):722-729. PubMed ID: 38379420
[TBL] [Abstract][Full Text] [Related]
2. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib Induces Dry Skin via Decreased in Aquaporin-3 Expression.
Ikarashi N; Kaneko M; Watanabe T; Kon R; Yoshino M; Yokoyama T; Tanaka R; Takayama N; Sakai H; Kamei J
Biomolecules; 2020 Apr; 10(4):. PubMed ID: 32260143
[TBL] [Abstract][Full Text] [Related]
3. Quantitative Tyrosine Phosphoproteomics of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-treated Lung Adenocarcinoma Cells Reveals Potential Novel Biomarkers of Therapeutic Response.
Zhang X; Maity T; Kashyap MK; Bansal M; Venugopalan A; Singh S; Awasthi S; Marimuthu A; Charles Jacob HK; Belkina N; Pitts S; Cultraro CM; Gao S; Kirkali G; Biswas R; Chaerkady R; Califano A; Pandey A; Guha U
Mol Cell Proteomics; 2017 May; 16(5):891-910. PubMed ID: 28331001
[TBL] [Abstract][Full Text] [Related]
4. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
[TBL] [Abstract][Full Text] [Related]
5. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
6. Daphnetin inhibits proliferation and inflammatory response in human HaCaT keratinocytes and ameliorates imiquimod-induced psoriasis-like skin lesion in mice.
Gao J; Chen F; Fang H; Mi J; Qi Q; Yang M
Biol Res; 2020 Oct; 53(1):48. PubMed ID: 33081840
[TBL] [Abstract][Full Text] [Related]
7. Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer.
Takeda M; Okamoto I; Nakagawa K
Lung Cancer; 2015 Apr; 88(1):74-9. PubMed ID: 25704957
[TBL] [Abstract][Full Text] [Related]
8. Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR-Mutated Non-Small Cell Lung Cancer.
Ding PN; Lord SJ; Gebski V; Links M; Bray V; Gralla RJ; Yang JC; Lee CK
J Thorac Oncol; 2017 Apr; 12(4):633-643. PubMed ID: 28007626
[TBL] [Abstract][Full Text] [Related]
9. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
[TBL] [Abstract][Full Text] [Related]
10. The Role of Brain Radiotherapy before First-Line Afatinib Therapy, Compared to Gefitinib or Erlotinib, in Patients with EGFR-Mutant Non-Small Cell Lung Cancer.
Jung HA; Park S; Lee SH; Ahn JS; Ahn MJ; Sun JM
Cancer Res Treat; 2023 Apr; 55(2):479-487. PubMed ID: 36596729
[TBL] [Abstract][Full Text] [Related]
11. Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(24):1-48. PubMed ID: 23074402
[TBL] [Abstract][Full Text] [Related]
12. [Effects of tumor necrosis factor-alpha/extracellular signal-regulated kinase pathway on migration ability of HaCaT cells and full-thickness skin defects in mice].
Zhao SH; Jin LB; Zhang JH; Zhang YM; Fan DL
Zhonghua Shao Shang Yu Chuang Mian Xiu Fu Za Zhi; 2023 Feb; 39(2):122-131. PubMed ID: 36878521
[No Abstract] [Full Text] [Related]
13. Acute Generalized Exanthematous Pustulosis Caused by Erlotinib in a Patient with Lung Cancer.
Komiya N; Takahashi K; Kato G; Kubota M; Tashiro H; Nakashima C; Nakamura T; Iwanaga K; Kimura S; Sueoka-Aragane N
Case Rep Oncol; 2021; 14(1):599-603. PubMed ID: 33976640
[TBL] [Abstract][Full Text] [Related]
14. The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer.
Yonesaka K; Kudo K; Nishida S; Takahama T; Iwasa T; Yoshida T; Tanaka K; Takeda M; Kaneda H; Okamoto I; Nishio K; Nakagawa K
Oncotarget; 2015 Oct; 6(32):33602-11. PubMed ID: 26418897
[TBL] [Abstract][Full Text] [Related]
15. Effect of retinoic acid on aquaporin 3 expression in keratinocytes.
Xing F; Liao W; Jiang P; Xu W; Jin X
Genet Mol Res; 2016 Mar; 15(1):15016951. PubMed ID: 26985947
[TBL] [Abstract][Full Text] [Related]
16. Cytokine regulation by epidermal growth factor receptor inhibitors and epidermal growth factor receptor inhibitor associated skin toxicity in cancer patients.
Paul T; Schumann C; Rüdiger S; Boeck S; Heinemann V; Kächele V; Steffens M; Scholl C; Hichert V; Seufferlein T; Stingl JC
Eur J Cancer; 2014 Jul; 50(11):1855-63. PubMed ID: 24857781
[TBL] [Abstract][Full Text] [Related]
17. Erlotinib Protects LPS-Induced Acute Lung Injury in Mice by Inhibiting EGFR/TLR4 Signaling Pathway.
Tao H; Li N; Zhang Z; Mu H; Meng C; Xia H; Fu L; Xu Y; Zhang S
Shock; 2019 Jan; 51(1):131-138. PubMed ID: 29438224
[TBL] [Abstract][Full Text] [Related]
18. Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence.
Lu S; Shih JY; Jang TW; Liam CK; Yu Y
Adv Ther; 2021 May; 38(5):2038-2053. PubMed ID: 33730350
[TBL] [Abstract][Full Text] [Related]
19. Adapalene Gel 0.1% Versus Placebo as Prophylaxis for Anti-Epidermal Growth Factor Receptor-Induced Acne-Like Rash: A Randomized Left-Right Comparative Evaluation (APPEARANCE).
Chayahara N; Mukohara T; Tachihara M; Fujishima Y; Fukunaga A; Washio K; Yamamoto M; Nakata K; Kobayashi K; Takenaka K; Toyoda M; Kiyota N; Tobimatsu K; Doi H; Mizuta N; Marugami N; Kawaguchi A; Nishigori C; Nishimura Y; Minami H
Oncologist; 2019 Jul; 24(7):885-e413. PubMed ID: 30890624
[TBL] [Abstract][Full Text] [Related]
20. Minocycline prevents and repairs the skin disorder associated with afatinib, one of the epidermal growth factor receptor-tyrosine kinase inhibitors for non-small cell lung cancer.
Sano K; Nakadate K; Hanada K
BMC Cancer; 2020 Apr; 20(1):279. PubMed ID: 32252690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
